loxoprofen has been researched along with Spasm in 1 studies
loxoprofen: RN given refers to parent cpd without isomeric designation; structure in first source
loxoprofen : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-[(2-oxocyclopentyl)methyl]phenyl group. A prodrug that is rapidly converted into its active trans-alcohol metabolite following oral administration.
Spasm: An involuntary contraction of a muscle or group of muscles. Spasms may involve SKELETAL MUSCLE or SMOOTH MUSCLE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Non-steroidal anti-inflammatory drugs (NSAIDs) are an effective and common treatment for chronic pain disorders, but long-term use is associated with risk of potentially life-threatening gastrointestinal adverse events (AEs)." | 2.78 | Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs. ( Kinoshita, Y; Miwa, H; Sugano, K; Takeuchi, T, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sugano, K | 1 |
| Kinoshita, Y | 1 |
| Miwa, H | 1 |
| Takeuchi, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use[NCT00595517] | Phase 3 | 395 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00595517)
Timeframe: up to 52 weeks
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole 20mg | 125 |
(NCT00595517)
Timeframe: up to 12 weeks after treatment
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 20mg | 127 |
(NCT00595517)
Timeframe: up to 24 weeks after treatment
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 20mg | 126 |
(NCT00595517)
Timeframe: up to 4 weeks after treatment
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole 20mg | 130 |
1 trial available for loxoprofen and Spasm
| Article | Year |
|---|---|
Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Esomeprazole; Fema | 2013 |